GlassScriptPhysician profile
Ely Salon
NPI 1396766051
$1,758.65
in general payments reported to CMS, 2019-2025
15 companies · $707 in 2025
The $707 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $62.71 · 2021: $93.17 · 2022: $47.85 · 2023: $386 · 2024: $97.89 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $292.33 | 2023-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $220.97 | 2021-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $204.29 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $169.83 | 2019-2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $164.62 | 2023-2025 | |
| Pfizer INC. | $146.57 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $116.51 | 2019-2025 | Zoryve |
| Dexcom, INC. | $113.62 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $80.64 | 2023 | Epclusa |
| Horizon Therapeutics Plc | $69.92 | 2019 | |
| Janssen Scientific Affairs, LLC | $55.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.40 | 2019 | |
| Lilly USA, LLC | $32.03 | 2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $28.96 | 2019 | |
| Abbott Laboratories | $23.96 | 2025 | Freestyle Libre 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ely Salon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.